What did @lauren.erro actually say?
Lauren is seven months into tirzepatide use, has lost 24 pounds, and describes her weight loss as slowing from about a pound a week to half a pound. She also says she recently bumped her dose to 4.25 mg. Two things stand out immediately: she calls tirzepatide a "GLP-2" and she mentions buying peptides herself rather than going through a prescriber. Both of those details deserve a closer look.
To her credit, she is transparent about what she is doing, including the uncertainty. She says "we'll see if that's a real thing or not" about sustainable weight loss, which is more honest than most GLP-1 content online. She is not selling anything. She is just documenting her experience. That matters when you are evaluating intent, though it does not fix the factual errors.
Does the science back this up?
The weight loss trajectory she describes is consistent with clinical data. No, tirzepatide is not a GLP-2. The plateau she describes is real and well-documented.
In the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), participants on tirzepatide lost an average of 20.9% of body weight over 72 weeks. Early loss is typically faster; the rate slows as the body adapts. Losing roughly a pound a week early and half a pound later is not a sign of failure. It tracks what the trials showed.
On the GLP-2 claim: tirzepatide is a dual GIP and GLP-1 receptor agonist. GLP stands for glucagon-like peptide. GIP stands for glucose-dependent insulinotropic polypeptide. There is a GLP-2 receptor, but tirzepatide does not target it. This is a meaningful distinction because GLP-2 agonists like teduglutide are used for intestinal conditions, not weight loss.
What did they get wrong (or right)?
The GLP-2 label is simply wrong. Tirzepatide targets GIP and GLP-1 receptors. Calling it a GLP-2 is not a minor slip. It spreads a specific misconception about how the drug works, and in a video with 36,000 views, that compounds fast.
The peptide purchasing situation is more concerning. Buying compounded or research peptides outside of a licensed prescriber relationship bypasses safety checks that exist for real reasons: dosing verification, sterility testing, contraindication screening. The FDA has warned repeatedly about unregulated peptide sources. Compounded tirzepatide from a licensed 503A or 503B pharmacy under a valid prescription is a separate category from self-sourced peptides, and the two should not be conflated.
What she got right: the idea that slower weight loss may be more sustainable has some support. Rapid loss is associated with higher rates of lean mass loss (Wilding et al., 2021, NEJM). Whether GLP-1 class drugs produce more sustainable loss long-term is still being studied, and her "we'll see" framing is appropriately humble.
What should you actually know?
Three things matter here if you are considering tirzepatide or already on it.
- Tirzepatide is a dual GIP/GLP-1 agonist, approved under the brand names Mounjaro and Zepbound. It is not a GLP-2. The mechanism distinction matters if you are trying to understand side effects, drug interactions, or why it works differently than semaglutide alone.
- Sourcing matters a lot. Peptides purchased outside a legitimate prescriber-pharmacy relationship have unknown purity, concentration, and sterility. A 2023 analysis found significant dosing inconsistencies in compounded GLP-1 products from unverified sources. Adverse events from contaminated peptides have been reported to the FDA.
- Dose adjustments should happen with a prescriber, not based on a self-assessed stagnation period. A month without loss does not automatically mean the dose needs to go up. It could mean water retention, hormonal changes, or normal plateau physiology.
If you are using tirzepatide and it is working, good. But the pathway to it matters for your safety, not just the outcome.